Stock LNTH LANTHEUS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Market Closed - Nasdaq
Other stock markets
 21:00:00 29/04/2024 BST 		5-day change 1st Jan Change
67.26 USD +2.59% Intraday chart for Lantheus Holdings, Inc. +6.64% +8.48%
04-18 B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating MT
03-07 Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing
Lantheus Holdings Says FDA Approves Expanded Use of Definity in Pediatric Patients
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients
Lantheus Names Amanda Morgan Chief Commercial Officer
Sector Update: Health Care Stocks Advance Pre-Bell Thursday
Lantheus Holdings Q4 Adjusted Earnings, Revenue Climb; Issues Q1, Full Year Guidance; Shares Rise
Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
Lantheus Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Lantheus Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Lantheus to Supply Imaging Agent for Alzheimer's Study
Lantheus Holdings, Inc. Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
Morning Briefing - Markt Schweiz
Sector Update: Health Care Stocks Stronger Late Afternoon
Lantheus Sued by Novartis Entities for Patent Infringement
Sector Update: Health Care Stocks Higher Friday Afternoon
Sector Update: Health Care
Bourse Zurich: le SMI finit en forme après l'inflation américaine
Novartis dépose plainte aux Etats-Unis pour violation de brevets
Novartis intenta causa in USA a Lantheus per violazione brevetto
Novartis geht in USA gegen Lantheus wegen Patentverletzung vor
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LNTH Stock
  4. News Lantheus Holdings, Inc.
  5. Other languages